Why did my doctor push Grail’s dubious cancer test?

A doctor recommended Grail's Galleri cancer blood test, but recent UK trial of 142,000 people showed it failed to reduce late-stage cancers despite early promise and $949 price tag.

endpoints.news

More data, costly standards and no end in sight: Pharma grapples with its clinical trials cost problem

US clinical trials, particularly in oncology, have become increasingly redundant, inefficient and expensive. And the growing costs come just as China’s biotech industry has blossomed.

endpoints.news

Are PD-1xVEGF bispecifics being tested in the wrong kinds of cancer?

Summit Therapeutics is running late-stage trials for biopharma’s buzziest drug in lung cancer, but some industry experts believe ivonescimab and other PD-1xVEGF bispecifics may better target another t...

endpoints.news

A fresh biotech has a radical plan to treat inflammation and allergies, setting its sights on Xolair

Startup Excellergy debuts with $70M Series A to develop drugs targeting allergic diseases, aiming to compete with Roche/Novartis' Xolair through new immune response approach.

endpoints.news

Merck wins approval of subcutaneous Keytruda, in bid to extend life of world's top-selling drug

FDA approves Keytruda Qlex, Merck's new subcutaneous formulation of Keytruda, offering more convenient administration and patent protection through 2039.

endpoints.news

The Fed cut interest rates by a quarter point. How much will it move the needle for biotech?

Biotechs and their investors have long called for lower interest rates since the pandemic’s free-flowing fundraising environment dried up a few years ago. But there are other challenges facing the industry.

endpoints.news

Pfizer has a VEGF bispecific strategy. And it’s very different than Summit’s

As Wall Street continues to digest this week’s disappointing results for Summit Therapeutics’ PD-1xVEGF bispecific cancer drug, Pfizer is primed to take advantage.

endpoints.news

Summit plays defense for the first time as questions loom over Phase 3 lung cancer readouts

Summit Therapeutics is facing fresh scrutiny after mixed Phase 3 trial results for its cancer drug ivonescimab, leading to a 25% stock drop and questions about FDA approval.

endpoints.news

A British mitochondrial startup wants to break ground in ALS and Parkinson's. It has £50M to try

NRG Therapeutics announced the close of a £50 million Series B round that should take it through a Phase 2 study in ALS and a Phase 1b trial in Parkinson’s.

endpoints.news

Summit says long-awaited data in Western patients are a success. But they come with caveats

Summit Therapeutics released a much-anticipated cut of ivonescimab data in North American and European lung cancer patients on Sunday,

endpoints.news

FDA approves Eisai and Biogen's subcutaneous Leqembi, gaining new ground in competition against Lilly

The FDA approved a new formulation of Eisai and Biogen’s Alzheimer’s drug Leqembi, an incremental step in the companies’ strategy to compete with Eli Lilly’s Kisunla.

endpoints.news

Amvuttra's first full-quarter sales for ATTR-CM are in. And they're a boon for Alnylam

A recent label expansion is sending sales of Alnylam’s Amvuttra through the roof. The drug pulled in $492.0 million in revenue in the second quarter, up 114% from the ...

endpoints.news

Vinay Prasad is out at FDA, following Sarepta decision and vaccine controversies

FDA's CBER head Vinay Prasad exits agency after Sarepta gene therapy controversy and criticism over Covid vaccine decisions. Conservative media targeted his political views.

endpoints.news

Celcuity posts Phase 3 win in breast cancer, setting up challenge to Novartis and Roche

Celcuity reports gedatolisib with fulvestrant reduced disease progression risk by 67% vs fulvestrant alone in Phase 3 breast cancer trial

endpoints.news

The FDA’s new SSRI experts have long questioned antidepressant use

FDA panel on antidepressant use in pregnancy features experts known for opposing medical consensus, includes discussion with Commissioner Marty Makary on Monday.

endpoints.news

Q&A: Retiring Arvinas CEO John Houston talks PROTACs, investor confidence and what’s next with Pfizer

John Houston is planning to retire at Arvinas after more than eight years at the helm, the company announced Wednesday, as its lead protein degrader program approaches an inflection point.

endpoints.news

FDA grants accelerated approval to datopotamab deruxtecan-dlnk

On June 23, 2025, the Food and Drug Administration granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.).

fda.gov

Biopharma leaders carving a path for the industry’s LGBTQ+ community

Welcome to the fourth edition of Endpoints News’ special report on scientists, executives, investors and other stakeholders in the biopharma’s LGBTQ+ community.

endpoints.news

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

CHICAGO — Gilead and Merck made a strong case for combining Trodelvy and Keytruda in the first-line setting for an aggressive form of breast cancer. The combination of Trodelvy and Keytruda ...

endpts.com

Summit’s disappointing survival readout raises stakes for full data

Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: How mature, exactly, were the data?

endpts.com

RFK Jr. Swims in Washington Creek That Flows With Sewage and Bacteria

nytimes.com

Pope Leo XIV Is A Sox Fan, Despite The Early Hope From Cubs Fans, His Brother Confirms

The Cubs' Marquee Sports Network, citing ABC News, said the new pontiff supports the North Siders. But his brother said that is not true.

blockclubchicago.org

Biotech stocks plunge and industry figures left to wonder after Prasad's FDA appointment

How did biopharma stocks react to Vinay Prasad’s appointment as director of one of the FDA's top jobs? Not well. Prasad, a hematologist-oncologist by training who gained prominence for criticizing ...

endpts.com

Bristol Myers' schizophrenia drug fails Phase 3 trial for adjunctive treatment

Bristol Myers Squibb’s attempt to turn Cobenfy into a megablockbuster neuroscience drug ran into a stumbling block Tuesday afternoon.

endpts.com

J&J's Duato says 'not tariffs, but tax policy' is best way to boost US manufacturing

The Johnson & Johnson CEO subtly but assertively criticized the Trump administration’s plans for pharmaceutical tariffs, saying they are not an effective tool to onshore drug manufacturing to the US.

endpts.com

Trump pharma tariffs inch closer as administration confirms US trade probe

Tariffs on pharmaceutical products that President Donald Trump has teased for weeks are one step closer to fruition after the Department of Commerce confirmed it's launched an investigation into the s...

endpts.com

Makary wants to replace animal testing with organoids. It may take a while

Under the 11-page 'roadmap' outlined Thursday, the goal is for alternative methods to become 'the exception rather than the norm' in the next three to five years.

endpts.com